1National Lung Screening Trial Research Team, Aberle DR, AdamsAM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011, 365: 395-409.
2Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366: 1527-1537.
3Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 2006, 1: 847-855.
4Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005, 353: 123-132.
5Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase II1 trial. Lancet, 2008, 372: 1809-1818.
6Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenoearcinoma. N Engl J Med, 2009, 361 : 947-957.
7Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell, 2009, 139: 871- 890.
8Subramanian G, Schwarz RE, Higgins L, et al. Targeting endogenous transforming growth factor-β receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotypel. Cancer Res, 2004, 64: 5200-5211.
